Acurx Pharmaceuticals trades on NASDAQ and is receiving FDA guidance supporting its potential approval pathway.
1 report, 1 independent
Updated Aug 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Acurx Pharmaceuticals trades on NASDAQ and is receiving FDA guidance supporting its potential approval pathway.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- RedHill Biopharma's stock surged on Nasdaq following the divestment of its Talicia business to Apotex for $18M, while future products seek FDA approval.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.